Oligomerix, Inc

Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. With a focus on oral, small molecule, tau self-association inhibitors, Oligomerix seeks to develop therapies for Alzheimer’s disease and other dementias that are easy to administer and cost effective, and which are expected to significantly add to newly emerging high-cost therapeutic options such as the monoclonal antibody targeted against beta-amyloid that was recently approved by the U.S. FDA. Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.

网站

https://oligomerix.com/

Oligomerix, Inc的外部链接

所属行业

生物技术研究

规模

11-50 人

总部

White Plains，New York

类型

私人持股

创立

2006

领域

Target discovery and validation、Drug discovery、Antibody discovery、Assay development、Pre-clinical development、Clinical development和Commercial development